The Week

CRISPR Therap (CRSP) rose 9.36% this week to close at $56.56, outperforming the S&P 500 by about 9.44 percentage points. The week’s amplitude was 15.6%, with average daily volume of roughly 2.36m shares, about 70% above the recent median. The move was not a straight line: the stock opened Monday at $51.33 and edged up to $52.96, pulled back to $51.83 on Tuesday, hovered near $52 on Wednesday, then jumped on Thursday to touch $59.21 intraday. Friday opened higher, hit $59.34, and faded into the close at $56.56, leaving a push-up-then-pull-back profile for the week.

Key Events

The main thread this week was gene editing’s move from lab to commercial reality. From Tuesday, several reports highlighted CASGEVY growth and year-end pipeline catalysts for CRISPR Therapeutics, while also widening the lens to Intellia and the commercial inflection across three gene therapy majors in 2026. On Monday, Cathie Wood’s Ark weekly recap noted buying in gene-editing names. Midweek, a market-focused note said CRISPR Therapeutics looked set to snap a six-session losing streak, which lined up with the stock stabilising early in the week and accelerating later. Friday’s coverage shifted to a longer horizon: where CRISPR Therapeutics could be in ten years if gene editing fulfils its promise. Overall, the week’s events were more about sector narrative and price action than company-specific earnings or regulatory news.

Analyst Ratings

As of 18 September 2026, 22 firms cover CRISPR Therap: 8 rate it buy, 5 rate it overweight, 9 rate it hold, and none rate it underweight or sell, so 13 firms rate it buy or overweight. The consensus rating is buy, with a consensus target of $87.56, which sits about 54.8% above the $56.56 close. The target range runs from $44 to $291, a wide spread that points to real disagreement about the pace of commercial execution. Within the biotech industry’s 501 companies, CRISPR Therap ranks 20th by analyst rating.

The Week Ahead

There are no CRISPR Therap earnings on the calendar next week, so attention shifts to macro data and sector sentiment. Tuesday brings the Richmond Fed composite index, Wednesday brings EIA crude inventory data, and Thursday includes initial jobless claims, new home sales, and natural gas storage. Jobless claims and new home sales may carry the most weight for risk appetite. For CRISPR Therap, the question is whether the stock can hold above $55 after this week’s volume-driven push higher, and whether gene-editing flows stick around.

In Short

CRISPR Therap outperformed this week with a 9.36% gain, backed by higher volume and Thursday’s sharp rise. The consensus rating is buy and the consensus target sits above spot, with a strong industry rank. But the target range spans nearly $247 from bottom to top, showing the market is far from aligned on how fast gene editing turns commercial, while the latest session’s large-lot flow leaned toward the sell side. The next test is whether the stock can hold its gains after this volume spike, and how year-end pipeline catalysts and macro mood rebalance from here.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.